Table 3.
Annual occurring and averted events in 2035
| Per 100 000 people | |||||
| Events | No intervention (CI) | 20% reduction (CI) | Difference (CI) | 50% reduction (CI) | Difference (CI) |
| T2D cases | 1034.6 (1031.0–1038.2) | 1014.7 (1011.3–1018.2) | 19.9 (12.8–27.0) | 951.2 (947.9–954.4) | 83.5 (76.7–90.3) |
| T2D deaths | 576.6 (574.2–578.9) | 569.3 (567.0–571.6) | 7.2 (2.7–11.8) | 546.4 (544.2–548.6) | 30.2 (25.7–34.6) |
| CHD cases | 665.1 (661.9–668.2) | 655.6 (652.5–658.8) | 9.4 (3.1–15.8) | 626.1 (623.1–629.1) | 39.0 (32.8–45.2) |
| CHD deaths | 203.6 (202.2–205.0) | 201.9 (200.5–203.3) | 1.6 (−1.2–4.4) | 197.2 (195.9–198.6) | 6.3 (3.6–9.1) |
| HCC cases | 4.4 (4.32–4.41) | 4.0 (3.95–4.05) | 0.3 (0.24–0.39) | 3.1 (3.02–3.18) | 1.3 (1.24–1.38) |
| Liver deaths | 19.8 (19.65–20.02) | 18.5 (18.29–18.63) | 1.4 (1.02–1.73) | 14.1 (13.94–14.21) | 5.8 (5.44–6.08) |
CHD, coronary heart disease; CI, 95% central coverage interval; HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis; T2D, type 2 diabetes.
Numbers might not add up due to rounding.